- The net 메이저 바카라 and operating profit for Q2 hit KRW110.3 billion and KRW56.7 billion, up 15.5% and 33.6% year-on-year, respectively
- The 메이저 바카라 overseas, led by the launch of the toxin in the US and expanded shipments to China this year, drive strong outcome
- Net 메이저 바카라 in cosmetics, the new growth engine, show a 104.5% increase year-on-year in Q2
[by Ji, Yong Jun] Hugel Inc., a leading global medical aesthetics company, announced on August 6th that its consolidated financial results for the second quarter of 2025 would be released on Wednesday. The company posted KRW110.3 billion in net sales, KRW56.7 billion in operating profit, and KRW38.2 billion in net income, representing year-on-year increases of 15.5%, 33.6%, and 3.3%, respectively. These results mark the highest quarterly figures in the company’s history and contributed to a record first-half performance.
For the first half of this year, the company’s cumulative net sales and operating profit exceeded KRW200 billion and KRW95 billion, respectively.
The company’s strong performance during the April-June period was driven by the overseas sales of its key products, botulinum toxin and hyaluronic acid filler. Overseas net sales of these products rose 21% year-on-year to KRW69.8 billion, accounting for 63% of the company’s total quarterly net sales.
The medical aesthetics leader, the first and only South Korean company that has won approval in the world’s three largest botulinum toxin markets – the US, China, and Europe – saw the exports of the key products make up 73% of the total toxin and hyaluronic acid filler sales in the second quarter, boosted by robust growth in these regions.
By product, botulinum toxin, domestically named Botulax and globally branded as Letybo, hit KRW61.2 billion in net sales for the second quarter with a 20% year-on-year increase and exceeded KRW100 billion in cumulative sales for the first half. The sales were backed by the additional shipments to the US in June, following the official launch in the country in March, and the steady growth in the Asia-Pacific markets such as China, Taiwan, and Australia.
The net 메이저 바카라 of hyaluronic acid filler, locally branded as THE CHAEUM and BYRYZN Skin Booster HA, reached KRW34.1 billion for the second quarter with solid growth in the APAC and European markets. The cosmetics brands, such as WELLAGE and BYRYZN BR, showed a 104.5% increase year-on-year to KRW13.6 billion in the same period.
“We achieved record quarterly net sales and operating profit with strong performances from the key products, botulinum toxin and hyaluronic acid filler, as well as our new growth driver cosmetics, and surpassed KRW200 billion in net sales for the first half,” a Hugel official said.
“In the second half, we will deepen our market penetration in the US with the toxin’s great quality and competitiveness, following the full-scale exports to the country, while keeping our focus on strengthening the market leadership in China and expanding the market share in the Middle East and emerging countries,” the official added.